1. Home
  2. FNWB vs MGNX Comparison

FNWB vs MGNX Comparison

Compare FNWB & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Northwest Bancorp

FNWB

First Northwest Bancorp

HOLD

Current Price

$9.96

Market Cap

87.9M

Sector

Finance

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.40

Market Cap

94.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWB
MGNX
Founded
1923
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.9M
94.9M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
FNWB
MGNX
Price
$9.96
$1.40
Analyst Decision
Buy
Hold
Analyst Count
1
5
Target Price
$13.50
$3.20
AVG Volume (30 Days)
31.1K
1.4M
Earning Date
01-28-2026
11-12-2025
Dividend Yield
1.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$54,052,000.00
$127,626,000.00
Revenue This Year
$31.86
N/A
Revenue Next Year
$10.64
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.47
N/A
52 Week Low
$6.05
$0.99
52 Week High
$12.10
$3.60

Technical Indicators

Market Signals
Indicator
FNWB
MGNX
Relative Strength Index (RSI) 64.85 44.77
Support Level $9.80 $1.32
Resistance Level $10.14 $1.47
Average True Range (ATR) 0.21 0.08
MACD -0.04 0.01
Stochastic Oscillator 46.15 34.78

Price Performance

Historical Comparison
FNWB
MGNX

About FNWB First Northwest Bancorp

First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: